India Globalization Capit... (IGC)
| Bid | 0.3 |
| Market Cap | 25.01M |
| Revenue (ttm) | 1.24M |
| Net Income (ttm) | -8.81M |
| EPS (ttm) | -0.12 |
| PE Ratio (ttm) | -2.61 |
| Forward PE | -2.86 |
| Analyst | Strong Buy |
| Ask | 0.32 |
| Volume | 891,299 |
| Avg. Volume (20D) | 345,329 |
| Open | 0.30 |
| Previous Close | 0.29 |
| Day's Range | 0.29 - 0.32 |
| 52-Week Range | 0.25 - 0.63 |
| Beta | 1.45 |
About IGC
India Globalization Capital, Inc. purchases and resells physical infrastructure commodities. It operates through two segments, Infrastructure and Life Sciences. The company rents heavy construction equipment, including motor grader and rollers; and undertakes highway construction contracts. It also develops cannabinoid-based products and therapies, such as hemp-based tinctures to treat anxiety, and enhance the lifestyle of patients suffering from...
Analyst Forecast
According to 2 analyst ratings, the average rating for IGC stock is "Strong Buy." The 12-month stock price forecast is $3.88, which is an increase of 1136.46% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
3 weeks ago · accessnewswire.com
IGC Pharma Announces CALMA Phase 2 Trial Expansion with the Addition of Miami Jewish HealthPOTOMAC, MD / ACCESS Newswire / April 1, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its Phase 2 clinical trial, CALMA, evaluating IGC-AD1 for the treatment of agitati...
1 month ago · accessnewswire.com
IGC Pharma Expands CALMA Trial with Addition of BayCare Health System in FloridaPOTOMAC, MARYLAND / ACCESS Newswire / March 17, 2025 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC Pharma" or the "Company") today announced the addition of a new trial site at BayCare's St. Anthony's ...
